All

Partnership Increases Accessibility to Covid-19 Tests in NYC

PerkinElmer, Inc. has announced its collaboration with the Mount Sinai Health System to increase accessibility of SARS-CoV-2 testing in New York City.

All

FDA Authorizes Software That Can Assist Prostate Cancer Diagnosis

The U.S. Food and Drug Administration (FDA) has authorized marketing of software to assist medical pathologists in detecting areas suspicious for cancer.

All

June 2021 Tech Guide: Immunoassay Analyzers

The Tech Guide from the June 2021 issue of Clinical Lab Products includes immunoassay analyzers from Beckman Coulter, Diazyme, Fujirebio, Grifols, Ortho Clinical Diagnostics, Randox, Siemens Healthineers, and more.

Diagnostic Technologies

BD Launches Cell Analyzer with Spectral Analysis Capabilities

The BD FACSymphony A5 SE Cell Analyzer is a fluorescence-activated, spectral-enabled cell analyzer, expanded to at least 34 parameters.

Lab Automation

AACC Urges Policies to Promote AI and Data Analytics in HealthCare

The AACC has released a position statement urging federal agencies to implement policies to fully harness the power of AI and data analytics.

Covid 19

Prescryptive Health Supplies Rapid COVID Testing to Florida Pharmacies

Prescryptive Health has partnered with CPESN Florida to bring COVID-19 rapid antigen testing and inventory management to CPESN Florida's member pharmacies.

Lab Equipment

Laser-Etched Bottom Rack ID Provides Permanence

Micronic has added an additional 2D Data-Matrix code on the bottom of the 96-1, 96-Q1, 96-2, 96-3 and 96-4 Micronic ULT Racks.

Lab Essentials

LIS Will Support Test Development Pipeline

Predictive Health Diagnostics Company (PHDC) has announced the rollout of its internally developed proprietary laboratory information system (LIS).

Disease States

British adults want blood tests which screen for cancer, study finds

A survey has found that 3 in 4 adults in the UK want more access to cancer screening, particularly as the COVID pandemic has begun to wane.

Lab Management

FDA Response to COVID Gives Insights for Regulatory Future of LDTs

Certain temporary deviations in FDA policy in response to the COVID-19 pandemic may offer a blueprint for regulatory oversight of LDTs.